In the first quarter of 2013, many famous investors either exited or reduced their positions in Cardinal Health, Inc. (NYSE:CAH). While Larry Robbins, Scott Black and Jim Simons sold out their positions, Joel Greenblatt and Paul Tudor Jones reduced their exposures to this stock. Indeed, Cardinal has recently lost several big contracts, implying declining sales over the next year.
Used to rely on two major customers
AmerisourceBergen took away the Walgreen contract
Many investors also worry about the recent lost of contract with its second biggest customer, Walgreen. Walgreen Company (NYSE:WAG) announced in March that it would not renew its contract with Cardinal Health, Inc. (NYSE:CAH), but rather be pursuing a 10-year agreement with AmerisourceBergen for daily drug distribution to Walgreens’ retail stores and specialty pharmacies. Moreover, Walgreen and its partner Alliance Boots also have the right to acquire up to 23% of AmerisourceBergen, including 7% open market purchase and 16% in warrants. This vertical integration will help all parties involved to increase operating efficiency, lower costs and gain bargaining power in the pharmaceutical industry. AmerisourceBergen Corp. (NYSE:ABC) is trading at $55.90 per share, with a total market cap of $12.9 billion. The market values the company at 9 times its trailing EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization).
The positive effect of the contract loss
Nevertheless, the loss of the contract with Walgreen has some positive effects on Cardinal Health, Inc. (NYSE:CAH)’s business. It expected lower working capital needs, thanks to the decreased inventory and accounts receivable when the Walgreen contract expires. In its Q3 2013 conference call, the company estimated that it could generate over $500 million in extra cash due to the reduced working capital, loss after-tax earnings and other cash tax impacts. Moreover, according to Barron’s, J.P Morgan thought that Cardinal Health could experience growth in its distribution margin, from 1.6% to more than 2% next year, because the contract losses mean putting an end to the low-margin businesses. EPS might experience a small decline in the next year, and then after that the business could have double-digit growth. Cardinal Health, Inc. (NYSE:CAH) is trading for lower valuation than AmerisourceBergen. At $48.80 per share, it is worth $16.70 billion on the market. The market values Cardinal Health at more than 7.5 times trailing EBITDA.
Lowest valuation but highest dividend yield
Another peer, McKesson Corporation (NYSE:MCK), has the highest valuation of the bunch. McKesson is trading at $114.60 per share, with the total market cap of nearly $26 billion. The market values McKesson at 9.75 its trailing EBITDA. McKesson has experienced 10% CAGR in adjusted EPS for the past four years, from $4.35 in 2009 to $6.33 in 2013. During this four year period, McKesson has deployed $15 billion, including $6.2 billion in acquisitions, $6 billion in share repurchases, $2 billion in internal capital spending and $800 million in dividends. Looking forward, McKesson Corporation (NYSE:MCK) expects to generate around $7.90 to $8.20 per share in adjusted EPS from continuing operations for the full year 2014.
Among the three companies, Cardinal Health, Inc. (NYSE:CAH) pays its shareholders the highest dividend yield at 2.5%. AmerisourceBergen ranks second with a 1.5% dividend yield, while McKesson offers the lowest dividend yield, at 0.7%.
My Foolish take
With the highest dividend yield, higher margin business, lower working capital needs and relatively low valuation, Cardinal Health seems to be a decent purchase upon its temporary short-term business setback.
Anh HOANG has no position in any stocks mentioned. The Motley Fool recommends McKesson. Anh is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.
The article Despite a Big Contract Loss, This Healthcare Service Company is a Buy originally appeared on Fool.com and is written by Anh HOANG.
Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
